دورية أكاديمية
أعرض في EDS

Placental transfer dynamics and durability of maternal COVID-19 vaccine-induced antibodies in infants.

التفاصيل البيبلوغرافية
العنوان: Placental transfer dynamics and durability of maternal COVID-19 vaccine-induced antibodies in infants.
المؤلفون: Lopez PA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA., Nziza N; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA., Chen T; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA., Shook LL; Massachusetts General Hospital, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Boston, MA 02114, USA.; Massachusetts General Hospital, Vincent Center for Reproductive Biology, Boston, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA., Burns MD; Massachusetts General Hospital for Children, Department of Pediatric, Boston, MA 02114, USA., Demidkin S; Massachusetts General Hospital, Vincent Center for Reproductive Biology, Boston, MA 02114, USA., Jasset O; Massachusetts General Hospital, Vincent Center for Reproductive Biology, Boston, MA 02114, USA., Akinwunmi B; Brigham and Women's Hospital, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Boston, MA 02115, USA., Yonker LM; Harvard Medical School, Boston, MA 02115, USA.; Massachusetts General Hospital for Children, Department of Pediatric, Boston, MA 02114, USA., Gray KJ; Harvard Medical School, Boston, MA 02115, USA.; Brigham and Women's Hospital, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Boston, MA 02115, USA., Elovitz MA; Women's Biomedical Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Lauffenburger DA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA., Julg BD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.; Harvard Medical School, Boston, MA 02115, USA., Edlow AG; Massachusetts General Hospital, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Boston, MA 02114, USA.; Massachusetts General Hospital, Vincent Center for Reproductive Biology, Boston, MA 02114, USA.; Harvard Medical School, Boston, MA 02115, USA.
المصدر: IScience [iScience] 2024 Feb 20; Vol. 27 (3), pp. 109273. Date of Electronic Publication: 2024 Feb 20 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, [2018]-
مستخلص: Completion of a COVID-19 vaccination series during pregnancy effectively reduces COVID-19 hospitalization among infants less than 6 months of age. The dynamics of transplacental transfer of maternal vaccine-induced antibodies, and their persistence in infants at 2, 6, 9, and 12 months, have implications for new vaccine development and optimal timing of vaccine administration in pregnancy. We evaluated anti-COVID antibody IgG subclass, Fc-receptor binding profile, and activity against wild-type Spike and RBD plus five variants of concern (VOCs) in 153 serum samples from 100 infants. Maternal IgG1 and IgG3 responses persisted in 2- and 6-month infants to a greater extent than the other IgG subclasses, with high persistence of antibodies binding placental neonatal Fc-receptor and FcγR3A. Lowest persistence was observed against the Omicron RBD-specific region. Maternal vaccine timing, placental Fc-receptor binding capabilities, antibody subclass, fetal sex, and VOC all impact the persistence of antibodies in infants through 12 months of age.
Competing Interests: The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. K.J.G. has consulted for Illumina, BillionToOne, and Aetion outside the scope of the submitted work. A.G.E. and M.A.E. serve as medical advisors for Mirvie. M.A.E. has equity in Mirvie outside the submitted work. B.D.J. is a part time employee of Leyden Laboratories B.V., Netherlands. B.D.J.’s immediate family member, Galit Alter, is a co-founder of SeromYx Systems, Inc., and has a patent on Systems Serology Platform pending.
(© 2024 The Authors.)
References: Vaccines (Basel). 2023 May 17;11(5):. (PMID: 37243095)
Signal Transduct Target Ther. 2022 Apr 26;7(1):138. (PMID: 35474215)
Viruses. 2022 Apr 29;14(5):. (PMID: 35632683)
Clin Dev Immunol. 2013;2013:427696. (PMID: 24066005)
Am J Reprod Immunol. 2010 Jun;63(6):425-33. (PMID: 20367629)
Nat Commun. 2023 Aug 10;14(1):4598. (PMID: 37563124)
Am J Obstet Gynecol. 2022 Sep;227(3):493.e1-493.e7. (PMID: 35430229)
Obstet Gynecol. 2021 Aug 1;138(2):278-280. (PMID: 33910219)
Sci Transl Med. 2021 Oct 27;13(617):eabi8631. (PMID: 34664972)
Lancet Infect Dis. 2017 Jul;17(7):e197-e208. (PMID: 28433705)
Lancet Infect Dis. 2022 May;22(5):581-583. (PMID: 35325619)
Nat Rev Immunol. 2020 Oct;20(10):633-643. (PMID: 32782358)
Nat Microbiol. 2023 Apr;8(4):569-580. (PMID: 37012355)
Front Immunol. 2015 Feb 23;6:77. (PMID: 25755655)
Clin Dev Immunol. 2012;2012:985646. (PMID: 22235228)
Immunol Rev. 2015 Nov;268(1):25-51. (PMID: 26497511)
Sci Transl Med. 2021 Oct 27;13(617):eabi7428. (PMID: 34664987)
Nat Commun. 2023 Feb 28;14(1):894. (PMID: 36854660)
Am J Obstet Gynecol. 2021 Aug;225(2):192-194. (PMID: 33812808)
Am J Obstet Gynecol. 2023 Jan;228(1):68.e1-68.e12. (PMID: 35868417)
Nat Commun. 2022 Jun 28;13(1):3571. (PMID: 35764643)
Am J Obstet Gynecol. 2021 Sep;225(3):303.e1-303.e17. (PMID: 33775692)
Cell. 2020 Dec 10;183(6):1508-1519.e12. (PMID: 33207184)
Obstet Gynecol. 2022 Mar 1;139(3):373-380. (PMID: 34963127)
Cell. 2021 Feb 4;184(3):628-642.e10. (PMID: 33476549)
Pediatr Infect Dis J. 2022 Mar 1;41(3):e81-e86. (PMID: 34955519)
Sci Immunol. 2023 Jan 27;8(79):eade2798. (PMID: 36548397)
Cell. 2019 Jun 27;178(1):202-215.e14. (PMID: 31204102)
N Engl J Med. 2023 Apr 20;388(16):1451-1464. (PMID: 37018474)
Am J Reprod Immunol. 1996 Nov;36(5):248-55. (PMID: 8955500)
Sci Immunol. 2023 Mar 31;8(81):eadg7327. (PMID: 36749191)
Sci Transl Med. 2022 Nov 23;14(672):eabn9237. (PMID: 35881018)
Nat Med. 2023 May;29(5):1155-1163. (PMID: 36959421)
J Immunol Methods. 2012 Dec 14;386(1-2):117-23. (PMID: 23023091)
Am J Obstet Gynecol MFM. 2022 Jan;4(1):100492. (PMID: 34547533)
JAMA. 2022 Mar 15;327(11):1087-1089. (PMID: 35129576)
JAMA Netw Open. 2023 Jul 3;6(7):e2323405. (PMID: 37450302)
N Engl J Med. 2022 Jul 14;387(2):109-119. (PMID: 35731908)
Front Immunol. 2019 Apr 12;10:805. (PMID: 31031776)
Front Immunol. 2020 Sep 11;11:1920. (PMID: 33013843)
MMWR Morb Mortal Wkly Rep. 2022 Nov 11;71(45):1442-1448. (PMID: 36355608)
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):264-270. (PMID: 35176002)
Am J Obstet Gynecol MFM. 2021 Nov;3(6):100481. (PMID: 34562636)
mBio. 2022 Aug 30;13(4):e0157722. (PMID: 35762593)
MMWR Morb Mortal Wkly Rep. 2022 Mar 04;71(9):352-358. (PMID: 35239634)
معلومات مُعتمدة: K08 HL143183 United States HL NHLBI NIH HHS; K12 HD103096 United States HD NICHD NIH HHS; U19 AI167899 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: Classification Description; Health sciences; Immunology; Microbiology; Pediatrics
تواريخ الأحداث: Date Created: 20240306 Latest Revision: 20240420
رمز التحديث: 20240420
مُعرف محوري في PubMed: PMC10914478
DOI: 10.1016/j.isci.2024.109273
PMID: 38444609
قاعدة البيانات: MEDLINE
الوصف
تدمد:2589-0042
DOI:10.1016/j.isci.2024.109273